Form 4: NewAmsterdam Pharma COO Granted 250,000 Stock Options

NewAmsterdam Pharma's Chief Operating Officer, Douglas F. Kling, was granted options to purchase 250,000 ordinary shares, vesting over four years.

Summary

• Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., was granted an option to purchase 250,000 ordinary shares.
• The options have an exercise price of $25.96 per share.
• The options vest over a four-year period, with 25% vesting on January 2, 2026, and the remaining 75% vesting in equal monthly installments over the following three years.
• The vesting is contingent upon Mr. Kling's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options aligns the COO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If Mr. Kling leaves the company before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The options will vest over the next four years, subject to the COO's continued employment.

Industry Context

Granting stock options is a common practice for incentivizing executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of executive compensation in the pharmaceutical industry.
• Vesting schedules of 3-4 years are typical for these types of grants.
• The specific terms of the grant, such as the exercise price and vesting schedule, are generally aligned with industry norms for companies of similar size and stage.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity compensation, executive compensation, vesting, NewAmsterdam Pharma, NAMS, Douglas F. Kling, COO